★ How regenerative medicine could revolutionize the treatment of trauma and osteoarthritis with Rigenera® technology

Regenerative medicine is one of the main medical trends in the treatment of pathologies from which patients suffer today. Rigenera®’s patented technology represents a radical change from current treatments in various therapeutic areas, providing a minimally invasive solution with rapid results for patients. Moreover, this is achieved in a single intervention, which is completed in less than half an hour without the need for hospitalization.

It works through the AMT (autologous micrografting technology) procedure, which is based on harnessing the regenerative potential of the body’s own mesenchymal cells or adult stem cells. When these cells are transferred to similar tissue in the body, they become therapeutic and their activity is limited to restoring cellular communication at the level of damaged tissue through various biological mechanisms.

Thus, it is an autologous and homologous treatment in which the same patient acts as the donor and hence there is no possibility of rejection of the injected cells and since they come from the same tissue being treated, this favors the specificity of the treatment.

This technology has many applications, including the treatment of osteoarthritis, a degenerative joint disease that affects cartilage, causing pain and limiting mobility. Osteoarthritis is currently one of the most affecting diseases in the population, as it is estimated to affect 30% of people over 40 years of age. In Spain this translates to a figure of around 7 million people, the impact of which goes beyond the health of the patient, but is the third cause of disability and with an annual cost per patient of 12,000 euros.

Moreover, due to the aging population, the prevalence has increased, and traditional solutions have not yet been able to stop its progression. Now, thanks to this new technology, one intervention is enough to stop the progression of osteoarthritis, relieve pain and improve the patient’s quality of life.

In the same way, it also helps eliminate knee pain by slowing down the breakdown of cartilage and the progression of osteoarthritis. It can also treat other joints affected by osteoarthritis, such as osteoarthritis of the big toe. This technology is especially useful for high-level athletes who, due to physical activity, suffer from degeneration earlier than expected.

Merger to reach more patients

Regenera Activa Worldwide and Rigenera HBW, biotechnology companies specializing in regenerative medicine, have teamed up under the Remedi brand to become global leaders and authorities in the field. The union of the Spanish company and the Italian company will add 50 employees in 4 countries and an annual turnover of more than 13 million euros. This is an ambitious move with the goal of maintaining annual growth at 20%.

Alexander Andreu, CEO of Regenera Activa Worldwide, states that with this alliance, “we are celebrating a new era in regenerative medicine worldwide. We add our know-how and commercial capabilities to Rigenera’s production and technological capabilities.”

For his part, Dr. Antonio GrazianoCEO of Rigenera HWB, stated that “this is a great opportunity to continue to popularize this revolutionary technology, doing so hand in hand with the scientific community, to continue to demonstrate new applications of Rigenera® in other areas of medicine that allow us to help more and more patients.”

Rigenera® technology is currently used by more than 50,000 physicians worldwide, and in 10 years, more than 400,000 procedures have been performed using this technology, benefiting millions of patients.

Numerous applications in regenerative medicine

The benefits of regenerative medicine extend beyond sports medicine and orthopedics, as other tissues in the body can be regenerated using the same technology. In fact, Rigenera® is also used in other therapeutic areas, such as in dermatology for hair regeneration or for the treatment of stretch marks. Opens up the possibility of use in the field of general medicine and traumatology for the healing of complex wounds. To achieve this goal, Remedi is collaborating with NATO (with rapid treatment kits) and with the European Space Agency (with the WHISPER project).

This collaboration, which also involves the University of Florence and the University of Pavia, responds to the challenges of treating wounds in non-serious situations. The wound healing process is biologically complex, and if natural processes are altered or blocked, they may have a worse prognosis or may become chronic.

This project, entitled “Wound Healing in Space: Challenges and Prospects in Tissue Regeneration and Engineering (WHISPER),” aims to investigate the use of Rigenera® to improve wound healing in cases of prolonged exposure to microgravity.

This study is another example of how Remedi, with Rigenera® technology, will be able to change medicine as we know it today, providing a fast and innovative solution to improve people’s health through the power of regenerative power. the human body’s own cells.

Fountain: DARE